Fedorova E A, Smolonogina T A, Isakova-Sivak I N, Koren'kov D A, Kotomina T S, Leont'eva G F, Suvorov A N, Rudenko L G
A. A. Smorodintsev Department of Virology, Institute of Experimental Medicine, St. Petersburg, Russia.
Department of Molecular Microbiology, Institute of Experimental Medicine, St. Petersburg, Russia.
Bull Exp Biol Med. 2018 Apr;164(6):743-748. doi: 10.1007/s10517-018-4071-4. Epub 2018 Apr 16.
A project of an experimental recombinant vector vaccine for prevention of diseases caused by pathogenic streptococci based on ScaAB lipoprotein of Streptococcus agalactiae and a coldadapted strain of live influenza vaccine as a vector was developed. The sequence of ScaAB lipoprotein was analyzed and fragments forming immunodominant epitopes were determined. Chimeric molecules of influenza virus hemagglutinin H7 carrying insertions of bacterial origin were constructed. Based on the results of simulation, the most promising variants were selected; they represented fragments of lipoprotein ScaAB lacking N-terminal domain bound to hemagglutinin via a flexible linker. These insertions should minimally modulate the properties of the influenza strain, while retaining potential immunogenicity to a wide group of pathogenic streptococci.
开发了一个基于无乳链球菌ScaAB脂蛋白和冷适应活流感疫苗株作为载体的预防致病性链球菌引起疾病的实验性重组载体疫苗项目。分析了ScaAB脂蛋白的序列并确定了形成免疫显性表位的片段。构建了携带细菌来源插入片段的流感病毒血凝素H7嵌合分子。根据模拟结果,选择了最有前景的变体;它们代表了通过柔性接头与血凝素结合的缺乏N端结构域的脂蛋白ScaAB片段。这些插入片段应能最小程度地调节流感毒株的特性,同时保留对多种致病性链球菌的潜在免疫原性。